Bictegravir pharmacokinetics in a late-presenting HIV-1-infected pregnant woman: a case report
Volume: 77, Issue: 3, Pages: 851 - 853
Published: Nov 18, 2021
Abstract
Bictegravir is an HIV integrase strand transfer inhibitor (INSTI) available as a once-daily fixed-dose combination tablet (bictegravir/emtricitabine/tenofovir alafenamide fumarate q24h). Combined ART (cART) is recommended for all HIV-infected pregnant women, to treat and prevent the sexual transmission of HIV and mother-to-child HIV transmission.1–3 Animal studies have shown no effect of bictegravir on fertility, reproductive performance or...
Paper Details
Title
Bictegravir pharmacokinetics in a late-presenting HIV-1-infected pregnant woman: a case report
Published Date
Nov 18, 2021
Volume
77
Issue
3
Pages
851 - 853
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History